Comparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE–Latin America study

Simple item page
dc.contributor.authorCarlos O. Mendivil
dc.contributor.authorEduardo Márquez-Rodríguez
dc.contributor.authorIván D. Ángel
dc.contributor.authorG Haro Y Paz
dc.contributor.authorC. Díaz Rodríguez
dc.contributor.authorJorge Almada
dc.contributor.authorOfelia Szyskowsky
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:53:15Z
dc.date.available2026-03-22T14:53:15Z
dc.date.issued2014
dc.descriptionCitaciones: 7
dc.description.abstractIn a usual care setting, patients treated with a vildagliptin combination succeeded in lowering A1c to <7%, without weight gain, hypoglycemia or peripheral edema more often than patients treated with comparator combinations, without increased risk of adverse events. Key limitations are the observational nature of the study and its relatively limited 12 month timeframe.
dc.identifier.doi10.1185/03007995.2014.928274
dc.identifier.urihttps://doi.org/10.1185/03007995.2014.928274
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/49131
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofCurrent Medical Research and Opinion
dc.sourceFundación Santa Fe de Bogotá
dc.subjectMedicine
dc.subjectVildagliptin
dc.subjectClinical endpoint
dc.subjectCohort
dc.subjectPopulation
dc.subjectInternal medicine
dc.subjectType 2 diabetes
dc.subjectDiscontinuation
dc.subjectDiabetes mellitus
dc.subjectHypoglycemia
dc.titleComparative effectiveness of vildagliptin in combination with other oral anti-diabetes agents in usual-care conditions: the EDGE–Latin America study
dc.typearticle

Files

Collections

Artículo Científico Publicado